Altimmune, Inc. entered into a securities purchase agreement for a registered direct offering of 17,045,454 shares of its common stock, or pre‑funded warrants, with a new institutional investor. The transaction is expected to close on or about January 29 2026 and will generate gross proceeds of roughly $75 million, after deducting placement agent fees and other offering expenses. Titan Partners, a division of American Capital Partners, is the sole placement agent for the offering, which is made pursuant to an effective shelf registration statement filed with the SEC on December 5 2025.
The company will use the net proceeds to support the preparation of its upcoming Phase 3 trial for pemvidutide in metabolic dysfunction‑associated steatohepatitis (MASH) and to fund general corporate purposes, including working capital. Pemvidutide has received Breakthrough Therapy Designation from the FDA for MASH, and the Phase 3 program is designed to deliver the 48‑week IMPACT readout and secure a regulatory meeting with the FDA. By financing this critical milestone, Altimmune aims to reduce the risk of a funding shortfall before the trial’s key data points and to maintain flexibility for future financing needs.
Prior to the offering, Altimmune reported $210.8 million in cash, cash equivalents, and short‑term investments as of September 30 2025, up from $131.9 million at the end of Q4 2024. The company also has a credit facility of up to $100 million from Hercules Capital. The $75 million raise is expected to extend the company’s financial runway beyond the 48‑week IMPACT readout, but it will also increase the share count and introduce dilution for existing shareholders. Investors have noted the trade‑off between the immediate capital infusion and the long‑term impact on earnings per share.
Management emphasized confidence in the program’s trajectory. “We are committed to advancing pemvidutide toward regulatory approval and believe this capital raise positions us well for the upcoming Phase 3 milestones,” said President and CEO Vipin K. Garg. While the market has reacted cautiously to the dilution implications, the company’s strategic focus on a high‑potential indication and its strong cash position underscore the importance of the funding for sustaining its clinical development pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.